Identification and management of patients with statin-associated symptoms in clinical practice: A clinician survey

G. Kees Hovingh, Shravanthi R. Gandra, Jan McKendrick, Ricardo Dent, Heather Wieffer, Alberico L. Catapano, Paul Oh, Robert S. Rosenson, Erik S. Stroes

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background and aims: Discontinuation of statin therapy by patients with hypercholesterolemia because of the onset of side-effects (statin-associated symptoms [SAS]) increases the risk of cardiovascular morbidity and mortality. We aimed to understand how patients with SAS, particularly those with statin-associated muscle symptoms (SAMS), are identified and managed in the outpatient setting.MethodsA web-based survey involving 60 clinicians in each of 12 countries and 90 clinicians in the US was conducted. Clinicians answered questions about the diagnostic criteria, estimated incidence of SAS, and choice of treatment for patients with SAS.ResultsOverall, 810 clinicians (78% cardiologists) completed the survey. An average of 72% of patients with potential SAS were reported to present with muscle-related symptoms (range across countries [RAC] 50-87%) that could be SAMS. Clinicians took a range of steps to confirm SAMS in these patients, including discontinuation of statin (average 59%; RAC 48-67%); re-challenge with ≥2 statins (average 74%; RAC 60-85%); modification of statin regimen (average 76%; RAC 65-85%); or a combination of these steps. Overall, 6% of patients with hypercholesterolemia were estimated to eventually have SAS (RAC 2-12%). In patients with SAS, on average 52% continued to receive a low-dose statin, usually with other lipid-lowering therapies (LLT). Of the remaining 49%, 38% received alternative LLT only; 11% did not receive any LLT.ConclusionThere is some consistency and stringency in clinical practice for identifying patients with SAS; however, a structured work-up for identification, followed by a defined therapeutic algorithm, may improve their management.

Original languageEnglish
Pages (from-to)111-117
Number of pages7
JournalAtherosclerosis
Volume245
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Muscles
Surveys and Questionnaires
Hypercholesterolemia
Lipids
Therapeutics

Keywords

  • Hypercholesterolemia
  • Statin
  • Statin intolerance
  • Statin-associated symptoms

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Identification and management of patients with statin-associated symptoms in clinical practice : A clinician survey. / Hovingh, G. Kees; Gandra, Shravanthi R.; McKendrick, Jan; Dent, Ricardo; Wieffer, Heather; Catapano, Alberico L.; Oh, Paul; Rosenson, Robert S.; Stroes, Erik S.

In: Atherosclerosis, Vol. 245, 01.02.2016, p. 111-117.

Research output: Contribution to journalArticle

Hovingh, G. Kees ; Gandra, Shravanthi R. ; McKendrick, Jan ; Dent, Ricardo ; Wieffer, Heather ; Catapano, Alberico L. ; Oh, Paul ; Rosenson, Robert S. ; Stroes, Erik S. / Identification and management of patients with statin-associated symptoms in clinical practice : A clinician survey. In: Atherosclerosis. 2016 ; Vol. 245. pp. 111-117.
@article{0c7d77c050514846b75433e2359090fd,
title = "Identification and management of patients with statin-associated symptoms in clinical practice: A clinician survey",
abstract = "Background and aims: Discontinuation of statin therapy by patients with hypercholesterolemia because of the onset of side-effects (statin-associated symptoms [SAS]) increases the risk of cardiovascular morbidity and mortality. We aimed to understand how patients with SAS, particularly those with statin-associated muscle symptoms (SAMS), are identified and managed in the outpatient setting.MethodsA web-based survey involving 60 clinicians in each of 12 countries and 90 clinicians in the US was conducted. Clinicians answered questions about the diagnostic criteria, estimated incidence of SAS, and choice of treatment for patients with SAS.ResultsOverall, 810 clinicians (78{\%} cardiologists) completed the survey. An average of 72{\%} of patients with potential SAS were reported to present with muscle-related symptoms (range across countries [RAC] 50-87{\%}) that could be SAMS. Clinicians took a range of steps to confirm SAMS in these patients, including discontinuation of statin (average 59{\%}; RAC 48-67{\%}); re-challenge with ≥2 statins (average 74{\%}; RAC 60-85{\%}); modification of statin regimen (average 76{\%}; RAC 65-85{\%}); or a combination of these steps. Overall, 6{\%} of patients with hypercholesterolemia were estimated to eventually have SAS (RAC 2-12{\%}). In patients with SAS, on average 52{\%} continued to receive a low-dose statin, usually with other lipid-lowering therapies (LLT). Of the remaining 49{\%}, 38{\%} received alternative LLT only; 11{\%} did not receive any LLT.ConclusionThere is some consistency and stringency in clinical practice for identifying patients with SAS; however, a structured work-up for identification, followed by a defined therapeutic algorithm, may improve their management.",
keywords = "Hypercholesterolemia, Statin, Statin intolerance, Statin-associated symptoms",
author = "Hovingh, {G. Kees} and Gandra, {Shravanthi R.} and Jan McKendrick and Ricardo Dent and Heather Wieffer and Catapano, {Alberico L.} and Paul Oh and Rosenson, {Robert S.} and Stroes, {Erik S.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.atherosclerosis.2015.12.015",
language = "English",
volume = "245",
pages = "111--117",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Identification and management of patients with statin-associated symptoms in clinical practice

T2 - A clinician survey

AU - Hovingh, G. Kees

AU - Gandra, Shravanthi R.

AU - McKendrick, Jan

AU - Dent, Ricardo

AU - Wieffer, Heather

AU - Catapano, Alberico L.

AU - Oh, Paul

AU - Rosenson, Robert S.

AU - Stroes, Erik S.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Background and aims: Discontinuation of statin therapy by patients with hypercholesterolemia because of the onset of side-effects (statin-associated symptoms [SAS]) increases the risk of cardiovascular morbidity and mortality. We aimed to understand how patients with SAS, particularly those with statin-associated muscle symptoms (SAMS), are identified and managed in the outpatient setting.MethodsA web-based survey involving 60 clinicians in each of 12 countries and 90 clinicians in the US was conducted. Clinicians answered questions about the diagnostic criteria, estimated incidence of SAS, and choice of treatment for patients with SAS.ResultsOverall, 810 clinicians (78% cardiologists) completed the survey. An average of 72% of patients with potential SAS were reported to present with muscle-related symptoms (range across countries [RAC] 50-87%) that could be SAMS. Clinicians took a range of steps to confirm SAMS in these patients, including discontinuation of statin (average 59%; RAC 48-67%); re-challenge with ≥2 statins (average 74%; RAC 60-85%); modification of statin regimen (average 76%; RAC 65-85%); or a combination of these steps. Overall, 6% of patients with hypercholesterolemia were estimated to eventually have SAS (RAC 2-12%). In patients with SAS, on average 52% continued to receive a low-dose statin, usually with other lipid-lowering therapies (LLT). Of the remaining 49%, 38% received alternative LLT only; 11% did not receive any LLT.ConclusionThere is some consistency and stringency in clinical practice for identifying patients with SAS; however, a structured work-up for identification, followed by a defined therapeutic algorithm, may improve their management.

AB - Background and aims: Discontinuation of statin therapy by patients with hypercholesterolemia because of the onset of side-effects (statin-associated symptoms [SAS]) increases the risk of cardiovascular morbidity and mortality. We aimed to understand how patients with SAS, particularly those with statin-associated muscle symptoms (SAMS), are identified and managed in the outpatient setting.MethodsA web-based survey involving 60 clinicians in each of 12 countries and 90 clinicians in the US was conducted. Clinicians answered questions about the diagnostic criteria, estimated incidence of SAS, and choice of treatment for patients with SAS.ResultsOverall, 810 clinicians (78% cardiologists) completed the survey. An average of 72% of patients with potential SAS were reported to present with muscle-related symptoms (range across countries [RAC] 50-87%) that could be SAMS. Clinicians took a range of steps to confirm SAMS in these patients, including discontinuation of statin (average 59%; RAC 48-67%); re-challenge with ≥2 statins (average 74%; RAC 60-85%); modification of statin regimen (average 76%; RAC 65-85%); or a combination of these steps. Overall, 6% of patients with hypercholesterolemia were estimated to eventually have SAS (RAC 2-12%). In patients with SAS, on average 52% continued to receive a low-dose statin, usually with other lipid-lowering therapies (LLT). Of the remaining 49%, 38% received alternative LLT only; 11% did not receive any LLT.ConclusionThere is some consistency and stringency in clinical practice for identifying patients with SAS; however, a structured work-up for identification, followed by a defined therapeutic algorithm, may improve their management.

KW - Hypercholesterolemia

KW - Statin

KW - Statin intolerance

KW - Statin-associated symptoms

UR - http://www.scopus.com/inward/record.url?scp=84950264089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84950264089&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2015.12.015

DO - 10.1016/j.atherosclerosis.2015.12.015

M3 - Article

AN - SCOPUS:84950264089

VL - 245

SP - 111

EP - 117

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

ER -